Amgen consensus steady ahead of next earnings, shares tracked against big pharma peers
26.06.2026 - 20:47:43 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 20:47.
Amgen (US0311621009) remains a closely watched large-cap biotech name on the NASDAQ. The stock carries a largely positive analyst consensus on Wall Street, according to current survey data from MarketScreener and other aggregators, with investors comparing it to big pharma peers such as Pfizer and Johnson & Johnson.
What current analyst surveys show
Recent analyst overviews compiled by MarketScreener indicate that a clear majority of covering houses rate Amgen shares at Buy or equivalent, while a smaller group sits at Hold and only a few at Sell, underlining a broadly constructive stance on the company.
Across the sample, average 12-month price targets cluster above the latest closing price, reflecting expectations for earnings growth from Amgen's diversified portfolio of oncology, immunology and cardiovascular therapies, as well as contributions from recently launched products and biosimilars.
How Amgen compares with peers
In terms of market positioning, Amgen sits alongside Pfizer, Johnson & Johnson and other global pharmaceutical groups in the large-cap health care universe, where investors scrutinize pipeline breadth, patent expiries and capital allocation policies when assessing the relative appeal of each stock.
On Wall Street, Amgen's valuation multiples are often compared with the S&P 500 health care sector as well as with individual rivals, with some analysts highlighting the company's balance between mature cash-generating drugs and newer assets aimed at sustaining revenue growth over the medium term.
All news and analysis on the Amgen shares
Track the latest headlines, analyst opinions and market data on Amgen in one place.
The product behind the stock
Amgen generates revenue primarily from innovative biopharmaceuticals in areas such as oncology, bone health and cardiovascular disease, including therapies for conditions like osteoporosis and high cholesterol, complemented by a growing business in biosimilars across major treatment classes.
The listing in brief
On the NASDAQ, Amgen shares most recently traded around 352.82 USD as of 2026-06-26, according to Investing.com data, placing the company firmly within the large-cap health care segment of the U.S. equity market.
Amgen at a glance
- Company: Amgen Inc.
- ISIN: US0311621009
- WKN: 867900
- Ticker: AMGN
- Trading venue: NASDAQ
- Price (as of 2026-06-26, 18:00): 352.82 USD
- Market cap: not verifiably stated (as of 2026-06-26)
- Sector / industry: Health Care - Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
